Nuvig Therapeutics, Redwood CityCA-based developer of therapies that induce immune homeostasis and treat autoimmune diseases without compromising normal immunity function, raised $47M. Series A funding.
TheRound was led by Novo Holdings A/S PlatanusParticipation from Bristol Myers Squibb, Digitalis Ventures, Mission BioCapital.
TheCompany plans to use the funds in order to expand its development efforts.
LedBy Pamela Conley, Ph.D., Chief Executive Officer, Nuvig Therapeutics offers protein therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inﬂammation, and improve the treatment options for patients. NuvigWe are developing a pipeline of immune therapies for chronic inflammatory diseases and autoimmune disorders.